BiotechTV

•

Channel • 5 Shows

Life Sciences

Life Sciences

Updated 31 May
Life Sciences

Life Sciences

Updated 5 days ago
Life Sciences

Life Sciences

Every two weeks
Life Sciences

Life Sciences

Updated 2 Feb
Life Sciences

Life Sciences

Updated 5 Mar

5 days ago

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.

5 days ago

•

47 min
5 May

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.

5 May

•

17 min
31 May

ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications

Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemotherapy, and he discusses the medicine's side effect profile. Plus, next steps for this treatment in pancreatic cancer and beyond.

31 May

•

13 min
23 Apr

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more.

23 Apr

•

42 min
15 Jun

Episode 42: Nextech's Thilo Schroeder

Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry.

15 Jun

•

1hr 5min
31 May

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.

31 May

•

35 min
15/08/2025

Biotech Direct: MassBio CEO Kendalle Burlin O'Connell and Seaport Therapeutics Founder & CEO Daphne Zohar discuss NIH funding, recent developments at FDA, and improving the public's view of science

In this inaugural episode of Biotech Direct, BiotechTV's new show that will share the biotech industry's perspective on policy and regulatory news, Kendalle Burlin O'Connell and Daphne Zohar discuss the strategic importance of biotech to the United States, share their thoughts on new FDA initiatives, and brainstorm ways to raise public awareness of the importance of science.

15/08/2025

•

33 min
02/06/2025

Episode 20: Breakout Ventures' Lindy Fishburne

Lindy Fishburne describes her educational background and career, and transitioning from the philanthropic Breakout Labs within the Thiel Foundation to Breakout Ventures, a traditional venture firm that has a diverse set of limited partners. Plus, how she is navigating these challenging times in healthcare and biotech.

02/06/2025

•

1hr 8min
19/08/2025

Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership

Interviewed by Xilio Therapeutics President & CEO René Russo, Dr. Liebisch describes her start in the industry as a patent attorney, discusses why having a champion in a larger partner is key, and explains why she even once threw a party when Vigil discontinued a candidate. Vigil Neuroscience was acquired by Sanofi earlier this year for an equity value representing approximately $470 million, plus a CVR.

19/08/2025

•

28 min
29/12/2025

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza

We discuss the upcoming maintenance data, commercial prospects, Crohn's, and buyout prospects.

29/12/2025

•

45 min

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Website

BiotechTV

Top Shows

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

Episode 42: Nextech's Thilo Schroeder

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

Biotech Direct: MassBio CEO Kendalle Burlin O'Connell and Seaport Therapeutics Founder & CEO Daphne Zohar discuss NIH funding, recent developments at FDA, and improving the public's view of science

Episode 20: Breakout Ventures' Lindy Fishburne

Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership

A deep dive discussion on Abivax with Truist Senior Biotech Analyst Gregory Renza

About

BiotechTV

Top Shows

Top Episodes

About